# Signature for Precise Chemosensitivity Prediction in PDAC

> **NCT06461598** · — · COMPLETED · sponsor: **Ruijin Hospital** · enrollment: 365 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT06461598
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2020-03-16
- **Final completion:** 2021-05-31
- **Target enrollment:** 365 (ACTUAL)
- **Last updated:** 2024-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06461598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06461598, "Signature for Precise Chemosensitivity Prediction in PDAC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06461598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*